Main Uses of Angimax MR

Angimax MR is primarily prescribed for the long-term treatment of stable angina pectoris. Angina is a clinical condition characterized by chest pain or discomfort that occurs when the heart muscle does not receive an adequate supply of oxygen-rich blood. This typically happens during physical exertion or emotional stress when the heart's demand for oxygen increases.

The medication is used as an add-on therapy for the symptomatic treatment of patients who are not sufficiently controlled by or are intolerant to first-line anti-anginal therapies. By improving the efficiency of cardiac energy metabolism, it helps the heart function more effectively under conditions of reduced oxygen supply.

Benefits and Mechanism of Action

Unlike traditional treatments that focus on altering heart rate or dilating blood vessels, Angimax MR works at the cellular level. The primary benefits include:

• Metabolic Support: It helps maintain the energy metabolism of heart cells during episodes of ischemia (reduced blood flow). By shifting the energy source from fatty acid oxidation to glucose oxidation, the heart requires less oxygen to produce the same amount of energy.
• Reduction in Angina Frequency: Regular use can lead to a decrease in the number of angina attacks experienced by the patient.
• Improved Exercise Tolerance: Patients may find they can engage in physical activity for longer periods before experiencing chest pain or discomfort.
• Decreased Need for Short-Acting Nitrates: As the baseline stability of the heart's oxygen management improves, the supplementary use of quick-relief medications for acute attacks may decrease.

Angimax MR is designed as a modified-release formulation, which ensures a steady release of the active ingredient into the bloodstream, providing consistent metabolic protection throughout the day.

Regulatory References

1. European Medicines Agency guidance

Angimax MR (trimetazidine) has strict population eligibility rules defined by official government regulatory documents, focusing primarily on pre-existing conditions and organ function.

Contraindicated Populations

Use of this medicine is prohibited for patients with:

• Movement disorders, including Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.
• Severe renal impairment, defined as a creatinine clearance (CrCl) less than 30 mL/min.
• Known hypersensitivity or allergy to trimetazidine or any of the inactive ingredients.

Restricted or Conditional Use

Special caution and/or dose adjustment are required for:

• Moderate renal impairment (CrCl in the 30-60 mL/min range).
• Elderly patients, particularly those over 75 years of age, due to expected increased exposure to the medicine.

Age-Group Eligibility

The medicine is only indicated for use in adults.

• It is not recommended for children and adolescents below 18 years because the safety and efficacy in this population have not been established.

Pregnancy and Breastfeeding

Use during pregnancy and breastfeeding is not recommended; medical advice should be sought before use.

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	None documented. Official prescribing information states that no drug–drug interactions have been reported.
Specific interacting medicines (if explicitly listed)	None explicitly listed. No specific co-administered medicines are reported as interacting with Trimetazidine dihydrochloride.
Mechanistic basis of interactions (only if stated in label)	None reported. No CYP-mediated, transporter-mediated, or pharmacodynamic interaction mechanisms are documented in regulatory sources regarding co-administered substances.
Timing-based interaction rules (if applicable)	None documented. No mandatory spacing or timing separation rules are listed for co-administration with other medicines.
Population-specific interaction notes (if applicable)	Moderate Renal Impairment (Creatinine clearance [30-60] mL/min): Increased exposure is documented due to reduced renal clearance. Elderly Patients (>75 years old): Increased exposure is documented due to age-related decrease in renal function.
Interaction-related restrictions	Food: No alteration of the drug's pharmacokinetic characteristics is documented when taken with foodstuffs.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification	Not applicable. No interactions with co-administered substances are assigned a severity classification (e.g., contraindicated, major, moderate).
Regulatory basis	Information derived from EMA-aligned Summary of Product Characteristics (SmPC) and other national regulatory documents.
Interaction-context constraints	Food: No interaction is documented to influence the drug’s pharmacokinetic characteristics.

---

Resulting Interaction Structure

Official interaction statements:

• No drug–drug interactions have been reported in official regulatory documents for Trimetazidine dihydrochloride.
• The pharmacokinetic characteristics of the drug are formally documented as not being influenced by meals or foodstuffs.
• Official documents note that Trimetazidine exposure is increased in patients with moderate renal impairment and in the elderly due to reduced renal clearance, requiring special caution.

The regulatory documentation defines this product's interaction structure primarily by the formal statement that no drug interactions have been reported with co-administered medicinal products. This documented absence means regulatory bodies do not specify any interacting product categories, contraindicated combinations, or mandatory timing separation rules. The only officially documented exposure alteration is the non-interaction-related pharmacokinetic caution concerning reduced renal clearance in specific patient populations.

The mechanism of Angimax MR is defined by its action as a metabolic anti-ischemic agent, focusing on modulating the internal energy substrate utilization in myocardial cells, a mechanism that does not directly alter hemodynamic factors such as blood flow or heart rate.

Modulating Myocardial Energy Pathways

The drug operates by engaging in metabolic modulation, targeting the mitochondrial enzyme Long-chain 3-Ketoacyl-CoA Thiolase (3-KAT), which is crucial for the heart's use of fatty acids as fuel. Angimax MR acts as a partial inhibitor of this enzyme, slowing the process known as fatty acid beta-oxidation. This inhibition reduces the rate of fatty acid beta-oxidation, which facilitates increased utilization of glucose for Adenosine Triphosphate ( ATP) generation.

️ Physiological Consequences: Oxygen Sparing and Cellular Stabilization

The shift toward glucose oxidation is physiologically relevant because glucose metabolism requires less oxygen to generate the same amount of ATP compared to fatty acid metabolism. This change in substrate utilization results in an effect of oxygen sparing. The resulting preserved ATP supports the function of ion pumps and exchangers, which regulates intracellular Ca^2+ and Na^+ concentrations, contributing to ion homeostasis. This stabilization of the cellular environment supports the functional resilience of the myocardial tissue during low-oxygen supply, which results in the cellular stabilization characteristic of its metabolic action.

Administration Principles for Angimax MR

Angimax MR (Trimetazidine dihydrochloride 35 mg Modified-Release tablet) is administered via the oral route as part of a chronic treatment plan. The standard regimen for adults involves taking one 35 mg tablet twice daily, resulting in a total daily dose of 70 mg. This schedule is generally divided into one dose taken in the morning and a second dose taken in the evening.

Administration Technique and Timing

The 35 mg modified-release tablet must be swallowed whole and should never be crushed or chewed; this is a strict requirement for maintaining the intended extended-release profile of the medicine. To ensure correct administration, the intake must occur during meals. If a scheduled dose is missed, the patient should skip the forgotten dose and simply resume the routine with the next dose at the scheduled time; doubling the dose is not permitted. The medicine is strictly confined to chronic therapy and is not to be used for the initial treatment of unstable angina or the management of acute cardiac events.

Population-Specific Use Rules

Usage is modified for specific populations based on renal function. For patients with moderate renal impairment (creatinine clearance between 30 and 60 mL/min), the labeled dose is reduced to one 35 mg tablet once daily, taken in the morning. This same adjustment rule applies to older adults who present with moderate renal impairment. The safety and effectiveness of Angimax MR have not been established in the pediatric population, and its use in individuals under the age of 18 is not recommended. The formal continuance of treatment must be assessed after three months to evaluate response and determine the need for further therapy.

Research evidence / Overview of studies for Angimax MR

---

Evidence for Use in Stable Angina Pectoris

The research base for Angimax MR primarily consists of Randomized Controlled Trials (RCTs), which form the structural basis for most regulatory clinical evaluation. These studies were used in research exploring how symptoms change over time when patients were administered this medication. In these trials, adult patients with stable angina pectorus were often studied while already receiving standard heart medications, with Angimax MR being evaluated as an add-on treatment.

Researchers examined outcomes related to physical discomfort, focusing on patient-reported outcomes describing perceived discomfort. Specifically, studies monitored the weekly number of angina attacks and the consumption of short-acting nitrates. Research also explored functional outcomes reflecting daily functioning, such as measuring the length of time patients could walk or exercise before they experienced chest discomfort, or before specific changes appeared during stress testing.

---

Evidence in Other Ischemic Heart Conditions

Research has also evaluated Angimax MR in study populations facing other conditions associated with acute or disruptive episodes, such as patients who have recently undergone cardiac procedures like stenting (PCI) or those with chronic heart conditions related to ischemia. These studies monitored physiological strain or stress in these patient groups.

Research examined outcomes that are linked to long-term heart health, such as major adverse cardiac events (MACE), which include serious issues like heart attack and cardiac mortality. In these longer-term research scenarios, findings were mixed. Trials designed to assess the effect on major prognostic events over follow-up durations that were limited did not provide definitive findings.

---

What is Still Uncertain About the Research

The research describes areas where the evidence landscape requires further development. One significant area is the lack of robust, long-term data establishing a clear relationship with major adverse cardiac events or overall survival, as the evidence quality varies across studies when examining these hard endpoints.

Furthermore, many initial trials focusing on outcomes related to physical discomfort had modest sample sizes and the follow-up durations were limited, meaning the certainty remains low regarding the persistence of measured patterns over many years. The existing evidence predominantly supports the agent's use as a supplementary or add-on treatment, meaning comparative evidence for its use as a first-line, single-agent therapy is lacking.

Common questions about Angimax MR (FAQ)

---

Q: How long does it typically take for Angimax MR to start providing a noticeable benefit?

The time it takes for this medicine to reach a stable concentration in the body is described in official pharmacokinetic studies for the modified-release formulation. The drug reaches its maximum concentration in the blood about five hours after taking a dose. A stable, consistent level of the medicine in the body, known as "steady-state," is generally reached after approximately 60 hours (two and a half days) of regular, chronic use.

---

Q: Is there any information about taking Angimax MR if I have liver issues?

According to the official regulatory information, no specific dosage adjustment is typically required for patients who have hepatic impairment (liver issues). This differs from renal (kidney) impairment, which is noted as an area for dose modification or contraindication. Information about how this medicine interacts with individual health conditions is best addressed by a healthcare professional.

---

Q: Are there different strengths or formulations of Angimax available besides Angimax MR?

Yes, the active substance, Trimetazidine, is available in multiple formulations and strengths, depending on the region. In addition to the modified-release (MR) tablet, the active substance is also available in an immediate-release tablet and sometimes an oral drop solution. The availability and use of different formulations are guided by regulatory approvals in each region.

---

Q: What are the rules regarding Angimax MR and professional sports or doping tests?

The active substance in Angimax MR, Trimetazidine, is classified as a prohibited substance by the World Anti-Doping Agency (WADA). It is listed as a metabolic modulator (Category S4) and its use is prohibited for athletes at all times, both during and outside of competition. This information is intended to clarify the official regulatory status for athletes and sporting bodies.

---

Q: Is Angimax MR generally considered non-sedating?

The official product safety information notes that the medicine may cause adverse reactions such as dizziness and drowsiness. Because these effects have been observed in some patients, the official safety information contains warnings regarding activities such as driving or operating machinery. The drug is not formally labeled as non-sedating.

---

Q: Can the active substance in Angimax MR be found under different brand names?

Yes, the active ingredient, Trimetazidine dihydrochloride, is a recognized substance that is marketed under many different trade names worldwide. Examples of other brand names containing this active ingredient include Vastarel MR and Preductal, among others. These different brand names all contain the same core medicine.

How to Store and Dispose of Angimax MR (Trimetazidine Modified-Release)

Official regulatory information for Angimax MR defines strict requirements to ensure product stability and safe disposal.

Storage Requirements

Storage Category	Official Instruction
Temperature Limit	Store at a temperature not exceeding 30^circC
Prohibited Environment	Do not store above 30^circC
Protection	Keep the medicine in its original packaging (e.g., blister pack) to maintain protection from environmental elements.

Disposal Instructions

All unused, expired, or waste material related to Angimax MR must be disposed of in accordance with local governmental and environmental regulations. The official instructions require adherence to established pharmaceutical waste disposal programs, such as medication take-back programs, rather than disposal in household trash or wastewater. This ensures environmental safety.